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Abstract
Background: Oral administration of magnesium and boron might have a beneficial
effect on headshaking behavior in horses.
Objective: Evaluate the effects of oral magnesium alone or in combination with
boron on headshaking behavior in affected horses.
Animals: Twelve geldings (6 healthy controls and 6 affected).
Methods: Prospective randomized controlled dietary trial over 42 days in 12 horses
(6 horses diagnosed with trigeminal-mediated headshaking and 6 unaffected healthy
controls). All horses received a hay diet and were randomized into 3 treatment groups:
pelleted feed combination (PF), pelleted feed combination with magnesium (M), and pel-
leted feed combination with magnesium-boron (MB) with a week washout of hay only
between treatments. Headshaking behavior and biochemical blood variables were
assessed at baseline (hay only) and then after each week of supplementation.
Results: All 3 diet interventions increased blood ionized and total magnesium. Groups
M and MB further increased Mg2+ when compared to PF. Horses receiving treat-
ments had a significant reduction in headshaking behavior, as measured by incidence
rate ratio (IRR), when compared to unsupplemented hay diet (44% for PF, IRR, 0.558;
CI, 0.44, 0.72; P < .001; 52% for M, IRR, 0.476; CI, 0.37, 0.62; P < .001; and 64% for
MB, IRR, 0.358; CI, 0.27, 0.48; P < .001).
Conclusions and Clinical Importance: Magnesium in combination with boron had the
greatest decrease in headshaking. Oral supplementation with magnesium or magne-
sium in combination with boron should be considered in horses affected with
headshaking.
K E YWORD S
equine, headshakers, magnesium, trigeminal
Abbreviations: AG, anion gap; H, hay diet; IRR, incidence rate ratio; M, magnesium supplement; MB, magnesium-boron supplement; PF, pelleted feed combination; SBE, standard base excess;
SID, strong ion difference; tMg, total magnesium.
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1 | INTRODUCTION
Trigeminal-mediated headshaking, formerly known as idiopathic
headshaking, is caused by a low threshold of firing of the trigeminal
nerve.1–3 Affected horses demonstrate abnormal behavior with head-
shaking such as sudden jerking of the head with a downward then
upward motion, rubbing the nose on their thoracic limbs or objects, lip
movements, and excessive snorting, noted mostly during exercise.1,4
The clinical signs of headshaking are suspected to result from neuro-
pathic pain, considering the low threshold for firing of the trigeminal
nerve in affected horses.2 The horse's behavior suggests neuropathic
pain that is manifested as an itching, burning, tingling, or electric-like
sensation.4,5 In most cases, clinical manifestation is seasonal with wors-
ening of signs during spring and summer months, and geldings are
overrepresented.4,6–9 Various treatments have been attempted to
alleviate the signs including physical devices such as face masks
with ultraviolet light protection, nose nets, nutritional supplements,
drug treatment, including administration of antidepressants, channel
blockers, antihistamines or corticosteroids, neuromodulation, and
caudal compression of the infraorbital nerve, among others.1,9–18
However, the results have been variable. Unsuccessful management
of this condition is associated with uncontrollable clinical signs often
leading to poor performance, wastage, and, in severe cases, euthana-
sia, representing an equine welfare issue.
An owner-based survey indicated that magnesium supplementa-
tion is perceived to decrease headshaking behavior in 40% of horses
affected with trigeminal-mediated headshaking.1,19 Owner-based sur-
veys have limitations such as the interpretation of signs and response
to treatment, familiarity with the disorder, confusion with other disor-
ders that might cause headshaking, and placebo effects. Some horses
affected with trigeminal-mediated headshaking have ionized magne-
sium concentrations below the reference range (mean of 0.44 ± 0.05;
reference range 0.47-0.70).20 Administration of intravenous magnesium
sulfate infusion given to horses affected with trigeminal-mediated head-
shaking significantly decreased headshaking behavior by 29%.21
Boron increases blood ionized magnesium concentrations.22 There-
fore, this study sought to evaluate the effects of dietary supplementa-
tion of magnesium and boron on headshaking behavior in horses.
We hypothesized that magnesium supplementation with or without
boron would decrease headshaking behavior in horses affected with
trigeminal-mediated headshaking. We also hypothesized that boron
would enhance absorption of magnesium, further increasing blood
concentrations of ionized magnesium and further decrease head-
shaking behavior.
2 | MATERIALS AND METHODS
2.1 | Animals
Twelve male castrated horses, Quarter Horse breeds (n = 8) and Thor-
oughbred (n = 4), aged 7 to 16 years, weighing between 465 and
636 kg were enrolled in the study. Six horses were diagnosed with
trigeminal-mediated headshaking and 6 healthy horses matched for
age and breed were selected as controls. The inclusion criteria of the
affected horses consisted of fulfillment of the diagnosis of trigeminal-
mediated headshaking by exclusion of other major causes of head-
shaking. Furthermore, these horses had been displaying headshaking
in a seasonal fashion in previous years and appearing normal in
between seasons. The lack of response to the administration of corti-
costeroids and antihistamines before donation did not support an
allergic component to headshaking behavior. All horses had previously
received all recommended vaccinations and deworming per University
of California Davis, Center for Equine Health protocols. Before enter-
ing the study, all horses underwent a thorough physical and neurologi-
cal examination performed by a board-certified large animal internist
and neurologist followed by a detailed diagnostic investigation.
Diagnostic investigation included oral, ophthalmic and otoscopic
examinations, CBC, serum biochemical profile, skull radiographs,
and endoscopy of the upper airway including guttural pouches.
None of the horses had apparent cervical or nuchal pain based on
palpation, extension, and flexion of the neck that could have con-
tributed to headshaking behavior. Computed tomography of the
head to further rule out other causes was not performed. Although
not part of this study, these horses were euthanized based on
humane grounds at a later time and postmortem macroscopic and
microscopic evaluation ruled out other possible causes of head-
shaking. All affected horses included in this study were displaying
headshaking behavior at the time of the experiments. Horses were
housed in covered box stalls bedded with wood shavings, having
free access to fresh water (automatic waterer), and dietary manage-
ment as listed below. This study was reviewed and approved by an
animal care and use protocol from our institution.
2.2 | Experimental design
The study was a randomized, controlled crossover experimental design,
where each horse served as its own control. The study was per-
formed during the spring in April and May. All horses throughout the
study received hay from the same batch (analyzed from Dairy One,
Ithaca, New York), alfalfa hay in the morning and grass hay in the
evening. Hay was weighed out based on body weight from baseline
measures so that horses received 1.5% of their body weight (BW) in
hay (H) per day. All horses underwent a control period of hay only
for 1 week at the beginning of the study before being randomized to
treatments. Supplements were weighed and provided to each horse
based on their individual BW as listed below. The horses were ran-
domized to 3 dietary treatment groups: (1) pelleted feed combina-
tion (PF) which served as control and consisted of 255 g of Purina
pelleted feed (Purina Equine Senior, Largo, Florida), 1/4 cup of canola
oil, and 2 tablespoons applesauce; (2) magnesium supplement (M) which
consisted of the same pelleted feed, oil and applesauce combination as
above plus 24.2 mg/kg BW of magnesium citrate (Magnesium Cit-
rate, Platinum Performance, Buellton, California); and (3) magnesium
and boron supplement (MB) which consisted of the same pelleted
feed, oil, and applesauce combination and magnesium citrate
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(Magnesium Citrate, Platinum Performance, Buellton, California); as
above plus 2 mg/kg BW of elemental boron (Boron Citrate = 40 mg/kg,
Platinum Performance, Buellton, California). There was a 1-week wash-
out period in between treatments where horses received no supple-
ments. The horses did not receive treatment in the same order
because treatment order was randomized. Additionally, free choice
water was provided with automatic waterers and tested for magne-
sium and boron levels to get a baseline value. The study period ran
from end of April and through the end of May during peak head-
shaking season for this group of horses.
2.3 | Sample collection
Blood samples (10 mL in evacuated tube containing heparin as antico-
agulant and 1.5 mL in heparinized syringes) were collected by veni-
puncture from the right jugular vein before initiation of dietary
supplementation (baseline) and after completion of a week of dietary
supplementation. All samples were collected before exercise and sam-
ples were placed on ice immediately and analyzed within 2 hours.
2.4 | Blood analysis
Venous blood pH, standard base excess (SBE), HCO3
−, Na+, Cl−, K+,
Ca2+, glucose, and lactate concentrations in heparinized blood sam-
ples were determined using an ABL815 FLEX (Radiometer America,
Inc., Brea, California). Total magnesium (tMg) and ionized magnesium
(Mg2+) in heparinized blood samples were determined using NOVA
8 (NOVA Biomedical, Waltham, Massachusetts). The strong ion dif-
ference (SID) was calculated using the Stewart equation as follows:
[(Na+ + K+ + Ca2+ + Mg2+) − (Cl−)].23 Anion gap (AG) was calculated
using the equation as follows: [(Na+ + K+) − (Cl− + HCO3−)].23
2.5 | Behavioral analysis
Horses were placed in an individual round pen, free from any tack or
halters, and evaluated by 3 independent experienced evaluators for
headshaking behavior while at a walk (1 minute), trot (1-3 minutes),
canter (1 minute), and walk again (1 minute) at baseline and then at
the end of each week of treatment. Exercise periods were videotaped.
Trot time varied because of concurrent lameness caused by navicular
disease in 2 horses (1-minute trot). This lameness was ruled out as
the cause of headshaking through perineural local anesthesia of the
palmar digital nerve. After the exercise period, horses were returned
immediately to their adjacent stalls. Evaluators were unaware of
which treatment each horse received at any particular day. The
headshaking behavior (including headshakes/minute, head-tossing/
minute, nose rubbing/minute, dropped head/minute, and snorting/
minute) was recorded for each horse during each level of exercise by
the 3 evaluators. A median value of headshaking behavior per minute
from the 3 evaluators for each horse during each level of exercise was
obtained. Agreement between evaluators was determined as described
under statistical analysis.
2.6 | Statistical analysis
Data were analyzed using software Stata Statistical Software, Release
14 (StataCorp LP 2015, College Station, Texas). A multilevel mixed-
effects Poisson regression model examined the main and interactive
fixed effects of treatment groups (H, PF, M, or MB), gait (walk, trot,
canter, or walk), and breed (Quarter Horse breeds or Thoroughbreds),
with individual horses as the random effect on headshaking behavior.
Each gait (first walk, trot, canter, and second walk) was evaluated sep-
arately. Each treatment was examined as the baseline value for further
effects. Results are presented as incidence rate ratios (IRRs), P values,
and 95% confidence intervals (CI). The variance among scorer
(the 3 trained evaluators) was evaluated statistically, using a Spe-
arman's rank correlation coefficient.
A multilevel mixed effects linear analysis of variance regression
model was also used to look at the main and interactive effects of
treatment groups (H, PF, M, or MB), status (control or headshaker)
with individual horse as random effect, on blood levels (pH, K+, Na+,
Cl−, SBE, HCO3
−, Ca2+, glucose, lactate, tMg, and Mg2+), and calcu-
lated values of SID and AG.
3 | RESULTS
3.1 | Blood results
3.1.1 | Statistical modeling
There was a significant increase in Mg2+ and tMg with all dietary
treatments (PF, M, and MB) when compared to baseline diet H for all
12 horses (Figures 1 and 2, P < .001). There was an interaction
between treatment MB and affected horses that caused a positive
effect on tMg (P = .02) and on Mg2+ (P = .043). There was a significant
F IGURE 1 Overall effect of treatment on venous tMg. The mean
and SEM venous blood tMg for all 6 control and 6 affected horses.
Black = control horses, gray = horses affected with headshaking.
Treatment H (hay only), treatment PF (pelleted feed combination),
treatment M (PF plus magnesium supplement), treatment MB (PF plus
magnesium and boron supplements). aSignificant differences than
treatment H for all horses. bSignificant differences than treatment PF
for all horses. cSignificant differences than treatment M for all horses.
P < .05 was considered significant
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difference on tMg (P < .001) between PF, M, and MB treatments com-
pared to H treatment. There was a significant difference on tMg
(P < .01) between M and MB treatments compared to PF treatment.
There was a significant difference on tMg (P = .012) between MB
treatment compared to M treatment. There was a significant differ-
ence in Mg2+ (P < .001) between PF, M, and MB treatments compared
to H treatment. There was a significant difference in Mg2+ (P < .01)
between M and MB treatments compared to PF treatment. There was
a significant difference in Mg2+ (P < .001) between MB treatment
compared to M treatment. Blood variables including pH, SBE, HCO3
−,
Na+, Cl−, K+, lactate, SID, AG, and Ca2+ had significant changes with
all treatments (PF, M, and MB) compared to H treatment (P < .001).
There was a significant increase in Ca2+ with all treatments (PF, M,
and MB) when compared to baseline diet H (Figure 3, P < .001).
3.1.2 | Effect of baseline hay diet on blood variables
At baseline (H), all blood variables were within reference range
except for SBE that were uniformly above reference range
(mean, 6.9 ± 0.8 mmol/L for controls; mean, 6.9 ± 1.3 mmol/L for
headshakers; Table 1), Mg2+ (mean, 0.45 ± 0.03 mmol/L for con-
trols; mean, 0.46 ± 0.03 mmol/L for headshakers; Table 1), and SID
(mean, 47.6 ± 1.7 mmol/L for controls; mean, 47.6 ± 2.5 mmol/L
for headshakers; Table 2).
3.1.3 | Effect of PF on blood variables
Treatment PF caused a decrease in SBE from baseline (H) but
remained above the reference range (mean, 4.3 ± 1.2 mmol/L for
controls; mean, 4.1 ± 0.9 mmol/L for headshakers; Table 1). There was a
decrease in Na+ in headshaker horses only (mean, 134 ± 1.1 mmol/L;
Table 1). There was an increase in Cl− to above reference range
(mean, 103 ± 1.6 mmol/L for controls; mean, 103 ± 1.0 mmol/L for
headshakers; Table 1). There was a decrease in AG to below refer-
ence range for all horses (mean, 7.5 ± 1.0 mmol/L for controls;
mean, 6.9 ± 0.6 mmol/L for headshakers; Table 2). There was an
increase in Ca2+ above reference range (mean, 1.62 ± 0.05 for con-
trols; mean, 1.64 ± 0.06 for headshakers; Table 1).
3.1.4 | Effect of magnesium supplement on blood
variables
Treatment M caused a decrease in SBE from baseline (H) but was still
above reference range (mean, 3.8 ± 1.7 mmol/L for controls; mean,
5.4 ± 1.9 mmol/L for headshakers; Table 1). There was a decrease in
Na+ in headshaker horses only (mean, 134 ± 1.0 mmol/L; Table 1).
There was an increase in Cl− to above reference range in control
horses only (mean, 103 ± 1.5 mmol/L for controls; Table 1). There
was a decrease in AG to below reference range for all horses
(mean, 7.7 ± 0.6 mmol/L for controls; mean, 6.2 ± 1.1 mmol/L for
headshakers; Table 2). There was an increase in Ca2+ above refer-
ence range (mean, 1.64 ± 0.03 for controls; mean, 1.64 ± 0.07 for
headshakers; Table 1).
3.1.5 | Effect of magnesium and boron supplement
on blood variables
Treatment MB caused a decrease in SBE from baseline (H) but was
still above reference range (mean, 4.8 ± 1.2 mmol/L for controls;
mean, 4.2 ± 0.3 mmol/L for headshakers; Table 1). There was a
F IGURE 2 Overall effect of treatment on the blood ionized
magnesium (Mg2+). The mean and SEM venous blood Mg2+ for all
6 control and 6 affected horses. Black = control horses, gray = horses
affected with headshaking. Treatment H (hay only), treatment PF
(pelleted feed combination), treatment M (PF plus magnesium
supplement), treatment MB (PF plus magnesium and boron
supplements). aSignificant differences than treatment H for all horses.
bSignificant differences than treatment PF for all horses. cSignificant
differences than treatment M for all horses. P < .05 was considered
significant
F IGURE 3 Overall effect of treatment on the blood ionized
calcium (Ca2+). The mean and SEM venous blood Ca2+ for all
6 control and 6 affected horses. Black = control horses,
gray = horses affected with headshaking. Treatment H (hay only),
treatment PF (pelleted feed combination), treatment M (PF plus
magnesium supplement), treatment MB (PF plus magnesium and
boron supplements). aSignificant differences than treatment H
for all horses. bSignificant differences than treatment PF for all
horses. cSignificant differences than treatment M for all horses.
P < .05 was considered significant
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decrease in Na+ for headshaker horses only (mean, 134 ± 0.8 mmol/L;
Table 1). There was an increase in Cl− to above reference range (mean,
103 ± 1.9 mmol/L for controls; mean, 103 ± 2.7 mmol/L for headshakers;
Table 1). There was a decrease in SID for headshaker horses only (mean,
37.3 ± 2.3 mmol/L; Table 2). There was a decrease in AG to below refer-
ence range for all horses (mean, 7.5 ± 0.8 mmol/L for controls; mean,
6.2 ± 1.3 mmol/L for headshakers; Table 2). There was an increase in
Ca2+ to above reference range (mean, 1.61 ± 0.05 mmol/L for controls;
mean, 1.62 ± 0.07 mmol/L for headshakers; Table 1).
3.2 | Behavior results
Control horses did not show signs of headshaking behavior and were
not included in the data that follows. In addition to headshaking, other
TABLE 1 Changes in blood variables after diet treatments H, PF, M, and MB
Treatments
H PF M MB
Blood variables Mean SD Mean SD Mean SD Mean SD
pH (ref 7.35-7.45)
Control 7.402 ±0.009 7.389 ±0.012 7.385 ±0.019 7.396 ±0.019
Headshaker 7.403 ±0.009 7.383 ±0.017 7.393 ±0.017 7.387 ±0.017
SBE mmol/L (ref −3.0 to +3.0)
Control 6.9 ±0.8 4.3 ±1.2 3.8 ±1.7 4.8 ±1.2
Headshaker 6.9 ±1.3 4.1 ±0.9 5.4 ±1.9 4.2 ±1.7
HCO3
− mmol/L (ref 25-32)
Control 31.7 ±0.9 28.9 ±1.2 28.6 ±1.6 29.5 ±1.0
Headshaker 31.7 ±1.3 28.9 ±0.9 30.1 ±1.8 28.9 ±1.7
Na+ mmol/L (ref 135-145)
Control 139 ±0.5 136 ±1.4 135 ±1.0 136 ±1.6
Headshaker 137 ±1.0 134 ±1.1 134 ±1.0 134 ±0.8
Cl- mmol/L (ref 94-102)
Control 97 ±2.3 103 ±1.6 103 ±1.5 103 ±1.9
Headshaker 96 ±2.6 103 ±1.0 102 ±2.3 103 ±2.7
K+ mmol/L (ref 3.3-5.0)
Control 3.8 ±0.2 4.1 ±0.4 4.3 ±0.3 4.1 ±0.2
Headshaker 4.0 ±0.4 4.5 ±0.4 4.4 ±0.5 4.4 ±0.6
Glucose mg/dL (ref 77-110)
Control 94 ±2 96 ±7 100 ±4 92 ±4
Headshaker 90 ±5 90 ±9 91 ±5 94 ±8
Lactate mmol/L (ref <2)
Control 0.5 ±0.1 0.8 ±0.1 0.8 ±0.1 0.7 ±0.1
Headshaker 0.6 ±0.1 0.8 ±0.1 0.8 ±0.1 0.7 ±0.1
Ca2+ mmol/L (ref 1.40-1.60)
Control 1.55 ±0.04 1.62 ±0.05 1.64 ±0.03 1.61 ±0.05
Headshaker 1.54 ±0.04 1.64 ±0.06 1.64 ±0.07 1.62 ±0.07
tMg mg/dL (ref 1.9-3.0)
Control 1.9 ±0.0 2.3 ±0.1 2.3 ±0.1 2.2 ±0.1
Headshaker 1.9 ±0.1 2.1 ±0.1 2.3 ±0.1 2.4 ±0.1
Mg2+ mmol/L (ref 0.47-0.70)
Control 0.45 ±0.03 0.54 ±0.04 0.56 ±0.03 0.53 ±0.05
Headshaker 0.46 ±0.03 0.51 ±0.07 0.55 ±0.09 0.59 ±0.09
Abbreviations: H, hay only, no supplement; M, pelleted feed combination, hay, and magnesium supplementation; MB, pelleted feed combination, hay, and
magnesium-boron supplementation; PF, pelleted feed combination and hay only.
Numbers in bold for the variables pH, HCO3, Na
+, Cl−, K+, glucose, Ca2+, tMg, and Mg2+ indicate values above or below the reference range.
Note. For SBE, the baseline values for all horses were above the reference range. For this variable, bold indicates difference from baseline values.
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signs displayed by the affected horses in a seasonal manner included
head-tossing, nose rubbing, dropped head, and snorting. However,
these signs were inconsistent and varied among horses. In order to
avoid more variability for the interpretation and quantification of
signs, other signs were excluded from further analysis. For the statisti-
cal analysis, we focused on the headshakes/minute as this was the
most important and consistent behavior of affected horses. Individual
headshaking frequency after 1 week of baseline diet H was used for
comparison with headshaking frequency after each week of dietary
supplementation. Horses receiving treatments PF, M, and MB had a
significant reduction in headshaking behavior when compared to
unsupplemented hay diet H (Figure 4; P < .001). Treatment MB is sig-
nificantly different than PF (Figure 4; P = .007). Treatment M was not
significantly different than treatment MB.
A mixed-effects Poisson regression model evaluated the effects
of treatment while controlling for breed and gait on median head-
shakes/minute. There was an effect of PF treatment controlling for
all breeds and gaits (walk, trot, canter, walk) with 0.56 times the rate
of headshakes per minute when compared to H, which results in a
44% reduction in median headshakes/minute (IRR, 0.558; CI, 0.44,
0.72; P < .001; Table 3). There was an effect of M treatment control-
ling for all breeds and gaits with 0.48 times the rate of headshaking
when compared to H, resulting in a 52% reduction in median head-
shakes/minute (IRR, 0.476; CI, 0.37, 0.62; P < .001; Table 3). There
was an effect of MB treatment, controlling for all breeds and gaits,
with 0.36 times the rate of headshaking compared to H, resulting in
a 64% reduction in median headshakes/minute (IRR, 0.358; CI, 0.27,
0.48; P < .001; Table 3). Effect of gait (trot and canter) and diet
treatment (PF, M, and MB) on IRR of median headshakes/minute are
shown in Table 4. There was an effect of gait when controlling for
breed and treatment with the trot and canter compared to the first
walk period with trot having almost 4 times increase in headshaking
(IRR, 3.750; CI, 2.65, 5.31; P < .001) and canter having almost 5 times
increase in headshaking (IRR, 4.700; CI, 3.34, 6.61; P < .001). For spe-
cific information about the number of headshakes per minute per
affected horse at the trot and canter, refer to Table S1.
3.2.1 | Treatment PF as control
The model was run with PF treatment as the control value. There was
an effect of H treatment with 1.78 times the risk of headshaking as
compared to PF treatment, resulting in a 79% increase in median
headshakes/minute (IRR, 1.789; CI, 1.39, 2.30; P < .001; Table 3).
There was an effect of MB treatment with 0.64 times the risk of
headshaking compared to PF treatment, resulting in a 36% decrease
in median headshakes/minute (IRR, 0.642; CI, 0.47, 0.88; P = .007;
Table 3). There were no significant differences between M treatment
compared to PF treatment.
3.2.2 | Treatment M as control
The model was run with M treatment as the control value. There
was an effect of H treatment with 2.09 times the risk of headshaking
compared to M treatment, resulting in a 2-fold increase in median
TABLE 2 Calculated SID and AG. Calculated changes in blood variables after diet treatments H, PF, M, and MB
Treatments
H PF M MB
Blood variables Mean SD Mean SD Mean SD Mean SD
SID mmol/L (ref 38-42
Control 47.6 ±1.7 38.6 ±1.9 38.5 ±1.9 39.0 ±0.8
Headshaker 47.6 ±2.5 37.9 ±1.3 38.5 ±2.7 37.3 ±2.3
AG mmol/L (ref 9-17)
Control 13.9 ±1.1 7.5 ±1.0 7.7 ±0.6 7.5 ±0.8
Headshaker 13.9 ±1.3 6.9 ±0.6 6.2 ±1.1 6.2 ±1.3
Abbreviations: H, hay only, no supplement; M, pelleted feed combination, hay, and magnesium supplementation; MB, pelleted feed combination, hay, and
magnesium-boron supplementation; PF, pelleted feed combination and hay only.
Numbers in bold indicated values above or below the reference range.
F IGURE 4 Overall effect of treatment on the headshakes per
minute at different gaits. The mean and SEM median headshakes per
minute for all 6 affected horses. Black circle = treatment H (hay only),
dark gray square = treatment PF (pelleted feed combination), gray
triangle = treatment M (PF plus magnesium supplement), light gray
diamond = treatment MB (PF plus magnesium and boron
supplements)
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headshakes/minute (IRR, 2.098; CI, 1.61, 2.73; P < .001; Table 3).
There were no significant differences between PF and MB treat-
ments compared to M treatment.
3.2.3 | Treatment MB as control
The model was run with MB treatment as the control value. There
was an effect of H treatment with 2.79 times the risk of headshaking
compared to MB treatment, resulting in an almost 3-fold increase in
median headshakes/minute (IRR, 2.786; CI, 2.08, 3.73; P < .001; Table 3).
There was an effect of PF treatment with 1.56 times the risk of
headshaking compared to MB treatment, resulting in a 56% increase
in median headshakes/minute (IRR, 1.557; CI, 1.13, 2.15; P = .007;
Table 3). There was not a significant difference between M treat-
ment and MB treatment.
3.3 | Agreement between evaluators
Spearman's correlation was run to assess interobserver variability of
3 evaluators. There was strong agreement between observer 1 and
2 (rs = 0.95; P < .0001), observer 1 and 3 (rs = 0.93; P < .0001), and
observer 2 and 3 (rs = 0.94; P < .0001).
4 | DISCUSSION
This study revealed a reduction in headshaking behavior with diets
providing magnesium supplementation. Horses receiving diet with
PF, M, and MB had significant reductions in headshaking behavior.
Despite the fact that there was great variability in the severity of
headshaking behavior between horses and variability of the same
horses on different days, the IRR analysis takes into account these
variables and provides a way to look at the effect of supplementation
in headshaking behavior. Combined magnesium-boron supplementa-
tion induced the highest IRR reduction (64%) in headshaking behavior
when compared to hay diet only. Similarly, magnesium-boron supple-
mentation had the greatest IRR reduction (36%) in headshaking behav-
ior when compared to a diet containing pelleted feed. The most
severely affected horses had the most benefit to supplementation pro-
viding magnesium (data not shown). As previously shown, as exercise
intensity increased headshaking behavior also increased.21
Diets of PF, M, and MB led to an increase in tMg and Mg2+ in
all horses. Affected horses had a further increase in tMg and Mg2+
when magnesium-boron supplementation was provided. The increased
response to boron should be investigated further. In absence of magne-
sium supplementation, as per baseline, values for Mg2+ for all horses in
this study (affected and control) were below reference range. It is
unclear whether supplementation would have similar effects if horses
had ionized magnesium within the normal reference range and fur-
ther investigation is warranted. Supplementation with all treatments
(PF, M, and MB) led to increases in blood levels of Ca2+ from base-
line (H) despite the fact that the additional amount of calcium was
small (approximately 2.55 g of total calcium). This is in contrast with
a previous study where Ca2+ was transiently decreased after admin-
istration of intravenous magnesium.21 The effects of Ca2+ increase
on headshaking behavior are not fully understood but possibly alter
the nerve resting membrane potential. Increased Ca2+ along with a
decreased Mg2+ likely bring the nerve resting membrane potential
closer to threshold.3,24 Furthermore, Mg2+ is also involved in the
regulation of neuroexcitation and can inhibit Ca2+-dependent presynaptic
TABLE 3 Effect of diet treatments (H, PF, M, and MB) on incidence rate ratio (IRR) of median headshakes/minute across all breeds and
controlled for headshaking horses only
Comparisons
Compared to H Compared to PF Compared to M Compared to MB
Treatment IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value
H – – 1.789 (1.39, 2.30) <.001 2.098 (1.61, 2.73) < .001 2.787 (2.08, 3.73) <.001
PF 0.558 (0.44, 0.72) <.001 – – 1.17 (0.87, 1.58) NS 1.557 (1.13, 2.15) .007
M 0.476 (0.37, 0.62) <.001 0.853 (0.63, 1.15) NS – – 1.328 (0.95, 1.85) NS
MB 0.358 (0.27, 0.48) <.001 0.642 (0.47, 0.89) .007 0.753 (0.54, 1.05) NS – –
Abbreviations: CI, confidence intervals; NS, not significant.
P < .05 was considered significant.
TABLE 4 Effect of gait (trot and canter) and diet treatment (PF, M,
and MB) on incidence rate ratio (IRR) of median headshakes/minute
across all breeds and restricted to headshaking horses only
Treatment IRR (95% CI) P value
PF
Trot 0.658 (0.45, 0.93) .020
Canter 0.460 (0.30, 0.71) .001
M
Trot 0.514 (0.35, 0.76) .001
Canter 0.396 (0.25, 0.63) <.001
MB
Trot 0.378 (0.25, 0.58) <.001
Canter 0.524 (0.34, 0.80) .003
Abbreviations: CI, confidence interval; M, pelleted feed combination,
hay, and magnesium supplementation; MB, pelleted feed combination,
hay, and magnesium-boron supplementation; PF, pelleted feed
combination and hay only.
P < .05 was considered significant.
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excitation-secretion coupling.25 Magnesium also acts on the neuro-
muscular blockade by inhibiting calcium channels.26
The requirement for magnesium in horses is 13 mg/kg BW and for
an average 500 kg horse, the requirement would be 6.5 g of magnesium
a day.27 Water would provide 510 mg of magnesium for a horse drink-
ing an average of 7.5 gal per day (standard range is 5-10 gal per day).28
Hay provided an average of 10 g of magnesium and with 45% average
bioavailability (ie, approximately 4.5 g of magnesium). The baseline diet
was calculated to provide 10 mg/kg magnesium for our group of horses.
The pelleted feed selected for this study provided 842 mg of magne-
sium based on the 255 g serving size per horse. This pelleted feed was
selected for palatability and its ability to help mask the flavors of the
added supplements and more specifically the boron supplement which
had a bitter taste. The addition of this specific pelleted feed in combina-
tion with applesauce and canola oil was not expected to greatly increase
Mg2+ nor affect headshaking behavior; however, it did in this group of
horses. Factors such as the canola oil and applesauce might have pro-
vided conditions to improve magnesium absorption. These effects were
not addressed in this study, but further studies in a larger population of
diseased horses could show insight into this intriguing finding. Also, it is
unknown if this finding (increase magnesium) would be observed with
other types of concentrates or pelleted feed.
The mechanism by which magnesium supplementation in the
form of magnesium alone or magnesium in combination with boron
resulted in significant reduction in headshaking behavior is not
completely understood. Treatment with magnesium in combination
with boron induced the greatest reduction (64% decrease in head-
shakes/minute) in headshaking behavior. This could be because of
boron's ability to increase magnesium concentrations in the blood.22
Magnesium can then provide its physiological channel blocking effects on
N-methyl-D-aspartate (NMDA) receptors and reduce ion currents.29–32
The NMDA receptors affect trigeminal neurons at the trigeminal
subnucleus caudalis (the orofacial nocioceptive processing center) in
rats.33 Boron can also affect neurotransmitters because of its ability to
form complexes with sugars.34 When boric acid forms ester complexes
with ribose, which is a part of adenosine, boric acid will noncom-
petitively inhibit adenosine diphosophate ribosyl cyclase (ADP-ribosyl
cyclase).35 This slows the production of cyclic ADP-ribose (cADPR)
which in turn slows down mobilization of Ca2+. Furthermore, calcium
might be involved in trigeminal neuropathic pain, but the exact mecha-
nism is unknown.36
The main limitations of the current study included the small num-
ber of horses and short-term duration of supplementation. A longer
duration of magnesium supplementation would have been useful to
investigate the long-term effects in headshaking behavior. The data
analyzed in this study included exclusively 1 clinical sign, head-
shaking. Therefore, the effects of magnesium supplementation in
other signs remain unknown. Various types of pelleted diets or con-
centrates were not evaluated in this study to investigate if the
effects on headshaking would have been similar to those found with
the PF used here. Our investigation included a short period of exercise
and not sustained exercise similar to what a rider would be performing.
Seasonality has a potential effect on severity of headshaking however
this study was performed within 6 weeks at the peak of headshaking
behavior in our group of horses as an attempt to minimize the effect
that seasonality could have played. Nerve conduction velocity of the
trigeminal complex before and after dietary supplementation would
have been a more objective manner to assess the effects of magne-
sium supplementation on the threshold for nerve firing. However,
this required general anesthesia and was not performed.
Although the overall decrease in headshaking behavior in this
group of 6 horses might not reflect the effects on the headshaking
population at large, this is a promising therapeutic option that should
be investigated in a broader population of horses affected with
trigeminal-mediated headshaking. Although magnesium supplementa-
tion did not completely alleviate all headshaking behavior, a reduction
might improve the horse's quality of life and performance, make a
horse rideable or manageable, and avoid euthanasia.
In conclusion, magnesium supplementation (PF, magnesium alone,
and magnesium in combination with boron) had effects on reducing
headshaking behavior in this small group of horses under the conditions
of the study. Magnesium in combination with boron appeared to
transiently reduce the severity of headshaking to a greater extent.
Magnesium supplementation could be considered, especially if ion-
ized magnesium is low as was found in the horses with headshaking
in this study. Supplementation with magnesium could be considered
as an adjunct to other treatment attempts for the management of
trigeminal-mediated headshaking.
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